| 摘要 |
The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of a dihydropyridine calcium channel antagonist such as Lercanidipine or salt thereof, in combination with colloidal silicon dioxide such as AerosilTM to enhance bioavailability and improve solubility, and a process for the preparation thereof by wet granulation. |
